Retatrutide Facts to Know Right Now As of April 9, 2026, retatrutide is still in Phase 3 trials and is not FDA-approved Lilly says it is legally available only inside Lilly clinical trials It is being studied as a once-weekly shot TRIUMPH-4 reported 28.7% average weight loss at 68 weeks on 12 mg TRANSCEND-T2D-1 reported 16.8% average weight loss at 40 weeks on 12 mg in adults with type 2 diabetes In TRIUMPH-4, tingling or burning skin was reported by 20.9% of people on 12 mg Lilly says more retatrutide results are expected over the next year The tracker basics stay simple: log the dose, mark the site, track symptoms, food, water, and weight Retatrutide may still be trial-only, but the weekly routine around it is real
Any deviation from this appearance indicates that the solution should not be used and represents a quality concern that should be addressed with your supplier
The current interpretation of their experience appeared to be a result of the efficacy of the medication and the difference it made in their ability to follow lifestyle behaviors
One practical implication of the shorter compounded shelf life: order smaller quantities more frequently rather than stocking up
A.CerajewskaT
However, the translational gap between the in vitro efficacy and the in vivo performance of many bioactive compounds (BACs) remains a major bottleneck in the development of efficacious nutraceutical products ( The core of this issue lies in the inherent physicochemical limitations of many BACs